Company profile: OmniSeq
1.1 - Company Overview
Company description
- Provider of genomic and immune tumor profiling solutions, offering OmniSeq INSIGHT for all solid tumors and research services including gene expression analysis, TCRβ repertoire profiling, PDL-1 IHC, transcriptome sequencing, and genome/exome sequencing.
Products and services
- Genome/Exome Sequencing: Delivers genome and exome sequencing as part of Research Services, generating comprehensive genetic datasets for investigators
- Research-grade
- OmniSeq INSIGHT: A pan-tumor assay that architects genomic and immune profiling for all solid tumors, offering physicians and patients actionable tumor-profiling information
- Assay-based
- Research Services: Offers genomic and immune profiling, gene expression, TCRβ repertoire and PDL-1 IHC, transcriptome sequencing, and genome/exome sequencing to support scientific investigations
- Multi-assay
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to OmniSeq
eLabNext
HQ: The Netherlands
Website
- Description: Provider of a digital lab platform for life science R&D with flexible lab information management software: eLabJournal (digital lab notebook for data, samples, protocols/SOPs), eLabInventory (secure sample management with inventory visualization), eLabProtocols (SOP management), a mobile app, cloud/private/on-premises hosting, and RackScan that reads racks with up to 96 barcoded vials; configurable with step-by-step implementation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full eLabNext company profile →
OpenEye
HQ: United States
Website
- Description: Provider of computational molecular design software and services, including the Orion Molecular Design Platform for cloud-based design and simulation (virtual screening, molecular dynamics, free energy predictions, quantum mechanics, sequence analysis), large-scale 2D/3D virtual screening, lead discovery and optimization, antibody discovery, and drug formulation; with strengths in 3D molecular shape and electrostatics analysis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OpenEye company profile →
GQ Life Sciences
HQ: United States
Website
- Description: Provider of life science information and search solutions: GenomeQuest, a patent search tool for DNA, RNA, and protein sequences with comprehensive comparison algorithms and a large indexed sequence database; and LifeQuest, a life science patent search platform using ontologies to understand biological queries and deliver complete, relevant results without false positives from non-life science patents.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GQ Life Sciences company profile →
NiKang Therapeutics
HQ: United States
Website
- Description: Provider of small-molecule oncology therapeutics, developing NKT2152, a HIF2α inhibitor in Phase 1/2 for clear cell renal cell carcinoma and other solid tumors; NKT3447, a reversible ATP-competitive CDK2 inhibitor in Phase 1 for solid tumors; KRAS G12D mutation inhibitors; and a SHP2 inhibitor being clinically evaluated by Erasca.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NiKang Therapeutics company profile →
Suvoda
HQ: United States
Website
- Description: Provider of clinical trial management software and services, including Suvoda IRT to manage drug distribution and patient dosing, eConsent to enable electronic trial participation consent, and eCOA to collect patient outcome data, backed by client services and integration services to streamline trial processes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Suvoda company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for OmniSeq
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to OmniSeq
2.2 - Growth funds investing in similar companies to OmniSeq
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for OmniSeq
4.2 - Public trading comparable groups for OmniSeq
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →